

CITATION REPORT

List of articles citing

A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia

DOI: 10.3324/haematol.2012.074633
Haematologica, 2013, 98, 881-7.

Source: <https://exaly.com/paper-pdf/57061940/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
68	Contemporary treatment of immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2013 , 6, 697-712	2.8	4
67	Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. <i>British Journal of Haematology</i> , 2013 , 163, 286-9	4.5	8
66	Clinical indications for thrombopoietin and thrombopoietin-receptor agonists. <i>Transfusion Medicine and Hemotherapy</i> , 2013 , 40, 319-25	4.2	43
65	A case of end-stage renal disease complicated by idiopathic thrombocytopenic purpura in which hemodialysis was initiated successfully with romiplostim. <i>Nihon Toseki Igakkai Zasshi</i> , 2014 , 47, 743-747	0.3	
64	PharmaForum. <i>Oncology Research and Treatment</i> , 2014 , 37, 426-429	2.8	
63	Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French Pharmacovigilance assessment. <i>European Journal of Internal Medicine</i> , 2014 , 25, 777-80	3.9	19
62	Thrombopoietic agents: there is still much to learn. <i>Presse Medicale</i> , 2014 , 43, e69-78	2.2	7
61	Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children. <i>Journal of Pediatrics</i> , 2014 , 165, 600-5.e4	3.6	44
60	Le romiplostim et l'eltrombopag ont-ils un profil d'effets indésirables différent ? Bilan de la Pharmacovigilance française (2009-2013). <i>Revue De Medecine Interne</i> , 2014 , 35, A69	0.1	0
59	Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2015 , 62, 208-213	3	51
58	Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. <i>Blood Research</i> , 2015 , 50, 19-25	1.4	18
57	Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. <i>International Journal of Hematology</i> , 2015 , 101, 255-63	2.3	40
56	Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis. <i>Annals of Hematology</i> , 2015 , 94, 339-41	3	6
55	Recommandations d'utilisation des agonistes du récepteur de la thrombopoïétine dans le purpura thrombopénique immunologique de l'enfant et de l'adolescent. <i>Revue D'oncologie Hématologie Pédiatrique</i> , 2015 , 3, 4-12		2
54	Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. <i>Drug Safety</i> , 2015 , 38, 1179-86	5.1	20
53	Use of eltrombopag after romiplostim in primary immune thrombocytopenia. <i>British Journal of Haematology</i> , 2015 , 169, 111-6	4.5	50
52	Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. <i>Seminars in Hematology</i> , 2015 , 52, 16-24	4	26

51	Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand. <i>Transfusion Medicine and Hemotherapy</i> , 2016 , 43, 375-379	4.3	11
50	Immunomodulation and immune thrombocytopenia: some unmet needs, questions, and outlook. <i>Seminars in Hematology</i> , 2016 , 53 Suppl 1, S39-42	4	1
49	Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 919-24	4.7	48
48	State of the art - how I manage immune thrombocytopenia. <i>British Journal of Haematology</i> , 2017 , 177, 39-54	4.5	71
47	Immune Thrombocytopenia: Where Are We Now?. 2017 , 749-760		
46	Therapeutic Use of Thrombopoietin Receptor Agonists. 2017 , 1417-1429		
45	Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center. <i>Annals of Hematology</i> , 2017 , 96, 507-508	3	8
44	Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres. <i>European Journal of Haematology</i> , 2017 , 99, 372-377	3.8	9
43	[Novelties in the treatment of pediatric immune thrombocytopenia - 2017]. <i>Orvosi Hetilap</i> , 2017 , 158, 1891-1896	0.8	
42	A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists. <i>British Journal of Haematology</i> , 2018 , 180, 591-594	4.5	3
41	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. <i>American Journal of Hematology</i> , 2018 , 93, 58-64	7.1	19
40	Immune Thrombocytopenia - Current Diagnostics and Therapy: Recommendations of a Joint Working Group of DGHO, ÖHO, SGH, GPOH, and DGTI. <i>Oncology Research and Treatment</i> , 2018 , 41 Suppl 5, 1-30	2.8	39
39	Immunthrombozytopenie - aktuelle Diagnostik und Therapie: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖHO, SGH, GPOH und DGTI. <i>Oncology Research and Treatment</i> , 2018 , 41 Suppl 2, 5-36	2.8	9
38	Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. <i>Therapeutic Advances in Drug Safety</i> , 2018 , 9, 263-285	3.5	23
37	Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2018 , 29, 374-380	1	8
36	Immune Thrombocytopenia. <i>New England Journal of Medicine</i> , 2019 , 381, 945-955	59.2	113
35	Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719837906	5.7	24
34	Thrombopoietin receptor agonists: ten years later. <i>Haematologica</i> , 2019 , 104, 1112-1123	6.6	116

33	Use of eltrombopag in aplastic anemia in Europe. <i>Annals of Hematology</i> , 2019 , 98, 1341-1350	3	18
32	Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27704	3	1
31	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019 , 3, 3780-3817	7.8	267
30	[Guideline for diagnosis and treatment of immune thrombocytopenia]. <i>Archivos Argentinos De Pediatría</i> , 2019 , 117, S243-S254	0.7	
29	Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia. <i>Platelets</i> , 2020 , 31, 291-299	3.6	2
28	Immune Thrombocytopenia: A Complex Autoimmune Disease. 2020 , 911-921		1
27	Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. <i>International Journal of Hematology</i> , 2020 , 111, 329-351	2.3	23
26	Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study. <i>International Journal of Hematology</i> , 2020 , 112, 787-794	2.3	6
25	Use of thrombopoietin receptor agonists after hematopoietic progenitor cell transplantation. <i>Advances in Cell and Gene Therapy</i> , 2020 , 3, e102	1.2	
24	Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists. <i>Journal of Comparative Effectiveness Research</i> , 2020 , 9, 447-457	2.1	6
23	[Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later]. <i>Revue De Medecine Interne</i> , 2021 , 42, 38-45	0.1	2
22	Update on diagnosis and treatment of immune thrombocytopenia. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 553-568	3.8	5
21	How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. <i>Blood</i> , 2021 , 137, 2736-2744	2.2	4
20	Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. <i>Drugs</i> , 2021 , 81, 1285-1305	12.1	9
19	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. <i>Blood Reviews</i> , 2021 , 49, 100811	11.1	4
18	Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study. <i>Blood Research</i> , 2021 , 56, 202-204	1.4	0
17	Recent advances in understanding and management of acquired thrombocytopenia. <i>F1000Research</i> , 2018 , 7, 68	3.6	4
16	Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim. <i>Blood Transfusion</i> , 2014 , 12 Suppl 1, s151-2	3.6	5

15	Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review. <i>Blood Transfusion</i> , 2018 , 16, 307-312	3.6	6
14	Thrombopoietin receptor agonists for the treatment of severe persistent and chronic immune thrombocytopenia in children: clinical data of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology. <i>Pediatric Hematology/Oncology and Immunopathology</i> , 2021 , 20, 12-25	0.3	1
13	Les thrombopénies immunologiques : physiopathologie et traitements. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2013 , 197, 407-417	0.1	
12	Immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2021 , 1-13	2.8	1
11	New Developments in the Pathophysiology and Management of Primary Immune Thrombocytopenia. <i>Hamostaseologie</i> , 2021 , 41, 275-282	1.9	1
10	The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia - single centre experience. <i>Vojnosanitetski Pregled</i> , 2021 , 90-90	0.1	
9	Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 795884	5.6	1
8	Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.. <i>Annals of Hematology</i> , 2022 , 101, 963	3	2
7	Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.. <i>British Journal of Haematology</i> , 2022 ,	4.5	1
6	Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP).. <i>Advances in Therapy</i> , 2022 , 1	4.1	
5	Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study. 2022 , 135, 2344-2350		0
4	Comprehensive analysis of primary immune thrombocytopenia clinical trials in the ClinicalTrials.gov database.		0
3	How we treat primary immune thrombocytopenia in adults. 2023 , 16,		0
2	Efficacy and safety of biosimilar romiplostim in Indian patients with chronic immune thrombocytopenia: A multicentric retrospective study. 2023 , 66, 96		0
1	Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. 2023 , 102, 715-727		0